List of Excipients in Branded Drug ANGELIQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	ANGELIQ	drospirenone and estradiol	50419-483	FERRIC OXIDE RED
Bayer HealthCare Pharmaceuticals Inc	ANGELIQ	drospirenone and estradiol	50419-483	HYPROMELLOSE
Bayer HealthCare Pharmaceuticals Inc	ANGELIQ	drospirenone and estradiol	50419-483	LACTOSE MONOHYDRATE
Bayer HealthCare Pharmaceuticals Inc	ANGELIQ	drospirenone and estradiol	50419-483	MAGNESIUM STEARATE

Angeliq Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: September 24, 2026

Angeliq is a fixed-dose oral hormone replacement therapy containing 1 mg estradiol and 0.5 mg drospirenone per tablet. Its commercial opportunity is concentrated in generic substitution, lower-cost manufacturing, differentiated tablet performance, and market-specific lifecycle products rather than biosimilar competition. The core excipient strategy should prioritize dose uniformity, chemical stability, dissolution control, patient tolerability, and manufacturing scalability.

What is Angeliq and which excipients does it contain?

Angeliq combines estradiol, an estrogen, with drospirenone, a spironolactone-derived progestogen with antimineralocorticoid activity. The combination is used for menopausal hormone therapy in women with an intact uterus, where the progestogen reduces the risk of endometrial hyperplasia associated with unopposed estrogen [1,2].

A publicly reported Angeliq tablet formulation includes the following excipient classes:

Formulation function	Representative excipient or material
Diluent	Lactose monohydrate
Bulking and compression aid	Corn starch
Disintegrant or compression aid	Pregelatinized starch
Binder	Povidone
Lubricant	Magnesium stearate
Film-forming polymer	Hypromellose
Anti-tacking and glidant material	Talc
Opacifier	Titanium dioxide
Colorant	Ferric oxide or another iron oxide pigment, depending on market

The precise qualitative and quantitative composition can vary by jurisdiction, manufacturing site, and registered product version. National product information should control any development or substitution decision [1,2].

The formulation presents a technical challenge because estradiol and drospirenone are both low-dose active pharmaceutical ingredients. A tablet containing 1 mg and 0.5 mg of active substances requires robust content uniformity controls. Excipient selection affects powder segregation, blend uniformity, tablet weight variation, disintegration, dissolution, and stability.

What is the optimal excipient strategy for an Angeliq generic?

The most defensible strategy is a conventional immediate-release, film-coated tablet using a low-risk excipient platform. A generic developer should avoid unnecessary formulation novelty unless it improves manufacturability, stability, or regulatory differentiation.

Blend uniformity and low-dose control

Drospirenone and estradiol represent a small fraction of total tablet mass. The formulation should use:

• A controlled particle-size distribution for both active ingredients.
• Geometric dilution or ordered blending.
• A carrier system that limits segregation during transfer and compression.
• A binder level sufficient to maintain granule integrity without slowing dissolution.
• In-process blend sampling at multiple manufacturing stages.

Direct compression may reduce processing steps, but wet granulation can provide better control of segregation and content uniformity if the active powders have poor flow or cohesive behavior. A high-shear wet-granulation process may be commercially attractive when it produces more consistent tablet weight and active distribution, but it introduces water and drying exposure that must be evaluated for estradiol stability.

Lactose and starch selection

Lactose monohydrate is commercially available, inexpensive, and familiar to regulators. It supports tablet mass and can improve compactability. Its principal limitations are moisture sensitivity, supplier variability, and potential incompatibility in formulations containing reactive amines. Those concerns are less central for estradiol and drospirenone than for amine-containing drug substances, but peroxide and moisture control remain relevant.

Corn starch and pregelatinized starch can support both binding and disintegration. The ratio between these materials affects hardness, friability, disintegration time, and dissolution. A developer seeking a direct-compression platform could evaluate microcrystalline cellulose or spray-dried lactose as alternatives, but changing the excipient system may increase comparative dissolution and bioequivalence risk.

Lubrication control

Magnesium stearate is a standard lubricant but can impair tablet wetting and dissolution when overmixed or used at excessive levels. The process should control:

• Lubricant concentration.
• Lubrication time.
• Shear during final blending.
• Tablet hardness and porosity.
• Dissolution after accelerated stability storage.

A lower-lubricant strategy, or replacement with sodium stearyl fumarate, may improve wetting in some designs. The commercial value is limited unless the change solves a demonstrated dissolution or manufacturing problem.

Film coating

A thin hypromellose-based coating is suitable for immediate-release tablets. It can protect the tablet from abrasion, improve swallowability, mask color variation, and provide product identification. Titanium dioxide and iron oxide pigments support appearance and light protection, although the use of titanium dioxide is subject to market-specific regulatory and commercial constraints.

A clear or pigment-reduced coating could lower cost and simplify supply in some markets. A colored coating may be preferable where brand recognition, counterfeit deterrence, and tablet differentiation have commercial value.

What formulation patents protect Angeliq-type products?

Angeliq-type products may be protected by patents directed to the combination of drospirenone and estrogen, pharmaceutical compositions, dosage regimens, and manufacturing processes. The relevant claims are more likely to focus on the active-ingredient combination and therapeutic use than on common excipients such as lactose, starch, povidone, or magnesium stearate.

A generic developer should analyze four claim categories:

Claim category	Commercial relevance
Drospirenone-estrogen combination	May cover the basic fixed-dose product
Specific dose ratio or dosing regimen	May affect product labeling and method-of-use risk
Immediate-release tablet composition	May capture specific excipient ranges or performance properties
Manufacturing or particle-size claims	May create process-design constraints

Routine excipients are generally weak patent differentiators unless a patent claims a defined quantitative combination, dissolution profile, particle-size distribution, coating system, or stability result.

How strong is the patent estate for Angeliq?

The estate is likely weaker against a well-designed generic than the estate surrounding complex biologics, depot products, transdermal systems, or modified-release formulations. Angeliq is an immediate-release tablet with established active ingredients and conventional excipients.

Potential strength remains in:

• Low-dose content-uniformity claims.
• Specific drospirenone or estradiol particle-size requirements.
• Stability claims involving oxidation, light, or moisture.
• Narrow composition claims.
• Method-of-use claims linked to menopausal symptom treatment.
• Manufacturing claims that are difficult to design around.

A formulation that uses different excipient grades, a different granulation route, and a distinct coating composition can reduce exposure to narrow composition or process claims. Patent clearance must be performed by jurisdiction because claim scope, prosecution history, supplementary protection rights, and litigation outcomes differ across countries.

When does Angeliq lose exclusivity?

Angeliq's practical exclusivity depends on the country, the active patent portfolio, regulatory exclusivity, product marketing status, and the availability of a reference product. The United States approved Angeliq under NDA 021355 in 2005, according to FDA records [3].

For an older small-molecule combination product, basic regulatory exclusivity is unlikely to remain the principal barrier in major markets. Commercial entry is more likely to depend on:

• Active Orange Book patent listings, if any.
• Paragraph IV certifications.
• State-specific product availability.
• Reference-product sourcing.
• Bioequivalence feasibility.
• Patent settlements.
• Commercial willingness to launch a low-volume hormone therapy product.

What is the Orange Book status of Angeliq?

The Orange Book status must be assessed against the relevant FDA NDA and current listing data. An applicant should distinguish among:

1. FDA approval history.
2. Current marketing status.
3. Active patent listings.
4. Regulatory exclusivity.
5. Drug-product availability for bioequivalence studies.

A product can retain an approval record while having limited or discontinued commercial distribution. That distinction affects the economics of an abbreviated new drug application.

Are there Paragraph IV challenges to Angeliq?

A Paragraph IV strategy would target any listed patent that is unexpired and relevant to the proposed generic. The applicant would need to assess whether the patent claims:

• The fixed-dose drospirenone and estradiol combination.
• The specific 0.5 mg/1 mg strength.
• A method of treating menopausal symptoms.
• A formulation parameter that the generic must reproduce.
• A manufacturing process used by the proposed product.

For an immediate-release tablet, a Paragraph IV case may be more attractive when the applicant can use an alternative excipient system and non-infringing manufacturing process. The principal litigation risk is claim construction around composition ranges, product-by-process language, dissolution limitations, and method-of-use labeling.

No reliable commercial conclusion should be drawn from the existence of a historical NDA alone. Current FDA patent listings and court records control the live Paragraph IV assessment [3,4].

What generic entry risks exist for Angeliq?

The principal generic risks are technical and commercial rather than biologic.

Technical risks

• Failure to demonstrate content uniformity for two low-dose actives.
• Dissolution differences caused by magnesium stearate or coating changes.
• Estradiol degradation during granulation, drying, or storage.
• Drospirenone particle-size effects on dissolution.
• Inconsistent tablet hardness and disintegration.
• Incompatibility between formulation changes and the reference product's in vivo performance.

Regulatory risks

• Difficulty obtaining reference product for comparative testing.
• Market-specific requirements for hormone-therapy labeling.
• Patent or method-of-use certification issues.
• Differences in inactive-ingredient acceptability across jurisdictions.
• Requirements to justify excipient changes beyond a simple composition comparison.

Commercial risks

Angeliq is a niche product relative to high-volume contraceptives and common generic cardiovascular medicines. A generic program requires a realistic estimate of:

• Annual prescription volume.
• Number of expected entrants.
• Reimbursement discounts.
• Distributor and pharmacy incentives.
• Manufacturing minimum batch size.
• Stability-testing burden.
• Cost of clinical or bioequivalence studies.

The fixed-dose combination can support pricing above an unbranded single-ingredient product if it offers convenience, but multiple generic entrants may rapidly compress margins.

What commercial opportunities exist in Angeliq excipients?

1. Low-cost generic tablet platform

The clearest opportunity is a conventional lactose-starch-povidone tablet with a simplified coating. This approach minimizes excipient cost, uses widely available suppliers, and reduces development complexity.

2. Premium excipient platform

A developer could use directly compressible excipients, improved flow grades, or co-processed materials to reduce granulation steps and improve batch consistency. The value comes from lower manufacturing cost and higher throughput rather than a premium patient claim.

3. Lactose-free formulation

A lactose-free version could address patients with lactose intolerance or markets where lactose-free positioning has commercial value. The substitution must preserve tablet mass, compactability, disintegration, and dissolution. Suitable alternatives may include microcrystalline cellulose, mannitol, dibasic calcium phosphate, or co-processed excipients.

4. Moisture- and light-protective packaging

Packaging is an important part of the formulation strategy. Blister packaging with high moisture and oxygen barriers may protect estradiol stability and improve shelf life. This can create a commercial advantage where bottle packaging causes moisture uptake or tablet degradation.

5. Differentiated dose strengths

A lifecycle program could assess additional estradiol or drospirenone strengths, but such products may require new clinical, regulatory, and patent analysis. A lower-estrogen option may have clinical demand, while a higher-strength product may face greater safety and labeling scrutiny.

6. Adjacent hormone-therapy products

The same manufacturing and excipient platform could support other oral estrogen-progestogen combinations. The value of the platform increases if it can be used across multiple strengths and products while maintaining common raw-material specifications and coating processes.

How does Angeliq compare with other menopause therapies?

Product type	Excipient and IP complexity	Commercial implication
Angeliq oral tablet	Low to moderate	Generic competition is technically feasible
Estradiol-only tablet	Low	Usually simpler, but lacks progestogen combination convenience
Estradiol/progestogen capsule	Moderate	Oil-based systems may create different stability and bioequivalence issues
Transdermal estradiol patch	High	Adhesive, membrane, and delivery-system IP can be stronger
Vaginal estrogen product	Moderate to high	Local delivery and device or applicator issues may raise barriers
Long-acting injectable hormone product	High	Manufacturing and clinical development costs are substantially higher

Angeliq has a lower formulation barrier than transdermal systems but a more demanding content-uniformity profile than many single-active oral tablets.

What is the biosimilar risk for Angeliq?

There is no biosimilar pathway for Angeliq. Estradiol and drospirenone are chemically synthesized small molecules. Competitive products would generally proceed through generic-drug pathways, national hybrid applications, or other small-molecule regulatory routes rather than the FDA biosimilar pathway.

Key Takeaways

• Angeliq is a 1 mg estradiol and 0.5 mg drospirenone immediate-release tablet.
• Its conventional excipient platform includes lactose, starch, povidone, magnesium stearate, and a hypromellose film coat.
• The highest technical risk is content uniformity for two low-dose active ingredients.
• A generic can likely design around many common-excipient claims, but active-ingredient combination, method-of-use, particle-size, stability, and manufacturing claims require jurisdiction-specific clearance.
• The strongest commercial opportunity is a low-cost generic with robust blend uniformity, stable dissolution, and moisture-protective packaging.
• Lactose-free, simplified-coating, and platform-based hormone-therapy products offer secondary lifecycle opportunities.
• Angeliq has generic rather than biosimilar competition.
• Current FDA Orange Book listings, NDA status, patent records, and market availability must be reviewed before a launch decision.

FAQs

Can a generic Angeliq use different excipients?

Yes. A generic may use different inactive ingredients if the formulation meets applicable quality, safety, equivalence, and regulatory requirements. The replacement must preserve tablet performance and avoid relevant patent claims.

Is Angeliq an extended-release product?

No. Angeliq is generally described as an immediate-release oral tablet. Its formulation strategy focuses on uniformity, disintegration, dissolution, and stability rather than controlled release.

Does magnesium stearate create a major Angeliq formulation risk?

It can. Excessive magnesium stearate or over-lubrication may reduce tablet wettability and slow dissolution. The risk is manageable through controlled concentration, blending time, and dissolution testing.

Could Angeliq be reformulated as a capsule?

Technically, yes, but a capsule would not be a simple generic substitution. It could change dissolution, stability, manufacturing controls, patient use, and regulatory requirements. It may also create a different patent and bioequivalence profile.

Is an Angeliq generic commercially attractive?

It can be attractive where the reference product has meaningful volume, limited generic competition, and favorable reimbursement. The opportunity is weaker in small markets with low prescribing, high bioequivalence costs, or multiple established generic competitors.

References

1. Bayer HealthCare Pharmaceuticals. (n.d.). Angeliq product information and prescribing information.
2. European Medicines Agency. (n.d.). Hormone replacement therapy product information and safety communications.
3. U.S. Food and Drug Administration. (2005). Drugs@FDA: Angeliq, NDA 021355.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.